Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates
Launched by ALBERT EINSTEIN COLLEGE OF MEDICINE · Feb 5, 2008
Trial Information
Current as of July 21, 2025
Terminated
Keywords
ClinConnect Summary
We will measure the rate of new insulin production in subjects with Type 2 diabetes compared to non diabetic subjects. We hypothesize that subjects with Type 2 diabetes make less insulin in response to GLP-1 compared to non diabetic subjects.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 2 Diabetes
- • Non diabetic
- Exclusion Criteria:
- • Currently taking medication such as thiazolidinediones, metformin, Exenatide, or sitagliptin
- • Chronic condition such as chronic heart failure CHF), Coronary Artery Disease (CAD), or chronic renal failure (CRF)
- • Anemia
About Albert Einstein College Of Medicine
Albert Einstein College of Medicine is a leading academic institution dedicated to advancing biomedical research and medical education. Situated in the Bronx, New York, it is renowned for its commitment to innovative research and training the next generation of physicians and scientists. The college actively engages in a wide range of clinical trials, focusing on translating scientific discoveries into effective therapies and improving patient care. With a collaborative approach that involves multidisciplinary teams, Albert Einstein College of Medicine aims to address significant health challenges and contribute to the global medical community through rigorous research and evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bronx, New York, United States
Patients applied
Trial Officials
Daniel T Stein, MD
Principal Investigator
Albert Einstein College of Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials